Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + busulfan + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This conditioning regimen, developed and investigated by the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, involves the addition of gemcitabine to a reduced-intensity backbone of busulfan and cyclophosphamide (BUCY2). It is designed for patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Gemcitabine, a pyrimidine antimetabolite, acts as a potent radiosensitizer and provides additional anti-leukemic activity by inhibiting ribonucleotide reductase and DNA polymerase. Busulfan and cyclophosphamide are alkylating agents that facilitate cytoreduction and immunosuppression. The combination aims to reduce relapse rates and improve survival outcomes in ALL patients by intensifying the conditioning regimen without prohibitive toxicity.
- Other names
- Gemcitabine plus reduced BUCY2Gemcitabine with Reduced BUCY2 Conditioning
02
Targets
DNA polymerase familyDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + busulfan + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + busulfan + cyclophosphamide.